Israel Englander Immunity Bio, Inc. Transaction History

Millennium Management LLC

$213 Billion
Q3 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 48,296 shares of IBRX stock, worth $100,455. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,296

Previous 3,243,706 98.51%

Holding current value

$100,455

Previous $8.56 Million 98.62%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.24 - $3.01 $7.16 Million - $9.62 Million	-3,195,410 Reduced 98.51%	48,296 $118,000
Q2 2025 Aug 14, 2025	BUY	$1.89 - $3.44 $5.32 Million - $9.68 Million	2,813,953 Added 654.78%	3,243,706 $8.56 Million
Q1 2025 May 15, 2025	BUY	$2.32 - $3.9 $453,965 - $763,132	195,675 Added 83.59%	429,753 $1.29 Million
Q4 2024 Feb 14, 2025	SELL	$2.56 - $6.17 $2.26 Million - $5.45 Million	-882,687 Reduced 79.04%	234,078 $599,000
Q3 2024 Nov 14, 2024	BUY	$3.32 - $6.7 $3.4 Million - $6.86 Million	1,023,174 Added 1093.24%	1,116,765 $4.14 Million

Q2 2024 Aug 14, 2024	BUY	$4.82 - $9.15 $189,146 - $359,064	39,242 Added 72.2%	93,591 $591,000
Q1 2024 May 15, 2024	SELL	$3.23 - $6.17 $19,247 - $36,767	-5,959 Reduced 9.88%	54,349 $291,000
Q4 2023 Feb 14, 2024	BUY	$1.25 - $5.21 $75,385 - $314,204	60,308 New	60,308 $302,000
Q1 2023 May 15, 2023	BUY	$1.35 - $4.78 $703,121 - $2.49 Million	520,831 New	520,831 $948,000
Q3 2022 Nov 14, 2022	SELL	$3.65 - $6.43 $2.85 Million - $5.02 Million	-780,514 Reduced 66.16%	399,271 $1.98 Million

Others Institutions Holding IBRX

# of Institutions

297

Shares Held

137M

Call Options Held

2.59M

Put Options Held

3.35M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $833M
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account